ENCePP aims through collaborative networking to optimise the conduct of post-authorisation studies by experienced researchers using available resources. In addition, ENCePP considers the availability of training opportunities in pharmacoepidemiology and pharmacovigilance as pivotally important in building future capacity in the European Union to undertake high quality, scientifically independent reserach. In line with this, ENCePP promotes postgraduate training opportunities offered by its partners and other centres.
Like ENCePP, the European Programme in Pharmacovigilance and Pharmacoepidemiology (Eu2P) and the Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium (PROTECT) projects aim to strengthen the monitoring of the benefit-risk of medicines in Europe.
The Eu2P training partnership is composed of seven Universities, the European Medicines Agency, the French Medicines Agency and fifteen pharmaceutical companies from the European Federation of Pharmaceutical Industries Association (EFPIA).
Eu2P is the first European online education and training programme in pharmacovigilance and pharmacoepidemiology. Master, PhD and Certificates are jointly awarded by Eu2P academic partners and recognized by all Eu2P regulatory and industrial partners. The programme is designed to be modular and flexible for graduate and postgraduate students in health and life sciences, for healthcare professionals and for non-specialists.
The Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium (PROTECT) was a collaborative European project that consisted in a comprehensive programme to address limitations of current methods in the field of pharmacoepidemiology and pharmacovigilance. Although the project is now closed, the PROTECT website provides direct links to results (databases, publications, presentations and the PROTECT Benefit/Risk website) that can be used as training material.
[Listings are grouped by country, but in no particular order and the ENCePP Secretariat neither endorses nor accepts any responsibility for the content/quality of any of the training courses listed. Please also see the ENCePP linking policy.]
» Department of Clinical Epidemiology, Aarhus University Hospital
The week-long course titled Assessing risks and benefits of treatments: methodological issues is a collection of advanced master classes taught by international experts in pharmacoepidemiology and comparative effectiveness research.
Registration deadline: 15 May 2018 (Early Bird registration by 1 March 2018)
Join the "Future Medicines Summer School - Gene & Cell Therapies" to learn about the promises and challenges of advanced therapies throughout the drug life cycle.In this course we will discuss all aspects of the drug life cycle and how these aspects influence the medicines of the future.
We will start at the early discovery of suitable drug targets and follow the path towards use through delivery, quality control and clinical development.
Finally, we will address the regulatory and financial aspects of innovative therapies.
This summer school is specifically interesting for anyone interested in the medicines of the future and their personalized use.
Day-to-day schedule: Future Medicines Summer School - Gene & Cell Therapies
Further information: Future Medicines Fellows
» Drug Safety Research Unit
» London School of Hygiene & Tropical Medicine